'Er status' presentation slideshows

NHSBSP Surgical QA Data for the Year of Screening 1 April 2002 to 31 March 2003

NHSBSP Surgical QA Data for the Year of Screening 1 April 2002 to 31 March 2003. Dr Gill Lawrence and Professor Jan Frisell on behalf of ABS at BASO. Acknowledgements. Mr Hugh Bishop Mr James Bristol Mr Mark Kissin Dr Gill Lawrence Mrs Julietta Patnick Ms Jacquie Reed.

763 views • 61 slides

CONGRES SFCP 2012 AJACCIO 11.5.2012

552 views • 47 slides

Tamoxifen Pharmacogenetics and Prediction of Breast Cancer Relapse After Administration of Tamoxifen

Tamoxifen Pharmacogenetics and Prediction of Breast Cancer Relapse After Administration of Tamoxifen. Matthew P. Goetz, MD Assistant Professor of Oncology Mayo Clinic College of Medicine. David Flockhart, MD, PhD

877 views • 45 slides

Steering Committee meeting, 24 th September 2005 University of Oxford Examination Schools

Steering Committee meeting, 24 th September 2005 University of Oxford Examination Schools. ATLAS and aTTom. Update on current status. adjuvant Tamoxifen Treatment: offer more?. ATLAS and aTTom study design. After several years on adjuvant tamoxifen,

412 views • 28 slides

Steering Committee meeting, 24 th September 2005 University of Oxford Examination Schools

Steering Committee meeting, 24 th September 2005 University of Oxford Examination Schools. ATLAS and aTTom. Update on current status. adjuvant Tamoxifen Treatment: offer more?. ATLAS and aTTom study design. After several years on adjuvant tamoxifen,

358 views • 28 slides

Statistical Review: Recursive Partitioning Identifies Patients at High and Low Risk for Ipsilateral Tumor Recurrence After Breast-Conserving Surgery and Radiation Freedman, Hanlon, Fowble, Anderson, and Nicolaou JCO, October 2002. Analytic Method: Recursive Partitioning Analysis

338 views • 20 slides

Discordance in hormone receptor status in breast cancer during tumour progression

265 views • 17 slides

Discordance in Hormone Receptor and HER2 Status in Breast Cancer during Tumor Progression

Discordance in Hormone Receptor and HER2 Status in Breast Cancer during Tumor Progression. Lindstrom LS et al. Proc SABCS 2010 ; Abstract S3-5. Background and Methods. Management of metastatic breast cancer (mBC) is routinely based on primary tumor ER/PR and HER2 status.

285 views • 8 slides

Fig. S1 Establishment of a sensitive and specific immunohistochemistry protocol to detect Mb

212 views • 5 slides